Полиморфизм гена альдостеронсинтазы у больных артериальной гипертензией в сочетании с ишемической болезнью сердца при различной массе миокарда левого желудочка

Abstract

Study purpose - assessment of the relationship of levels of aldosterone and natriuretic peptide plasma aldosterone synthase gene polymorphism variants in patients with coronary heart disease (CHD) in combination with arterial hypertension (AH) at different left ventricular mass.Materials and methods. The study involved 63 male with hypertension and CHD; there were 32 men with signs of left ventricular hypertrophy (LVH) and 31 men with coronary artery disease with hypertension with a normal index of left ventricular mass. Evaluated the concentrations of aldosterone and plasma natriuretic peptide (NUP) in the relationship with characteristic of aldosterone synthase gene polymorphism.Results. It is established that the genotype CYP11В2 T/С of is associated with increased levels of aldosterone and signs of left ventricular hypertrophy. The level of LVC in the signs of LVH group was 2,1 fold higher than in patients without LVH. For patients with evidence of left ventricular hypertrophy is characterized by: the genotype of CYP11В2 T/C (62,5% of cases), the identification of the T allele (1,3 times more likely than patients without evidence of LVH) and more rarely than with normal index of left ventricular mass occurs variant CYP11В2 T/Т and more rarely prevalent allele C. Conclusion. In patients with coronary artery disease and hypertension, it is reasonable to implement in practice population genetic analysis to assess the probability the formation of left ventricular hypertrophy in the early stages of the disease.